Dr. Naruporn Monmaturapoj
Assistive Technology and Medical Devices Research Center (A-MED), 111 Thailand Science Park, T. Klong Nueng, A. Klong Luang, Pathum Thani 12120, Thailand
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
6Years (2021-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications
Journal Article
WISITSIN POTIPRAPANPONG
Whithipa ThepveeraCKchutikarn khamsuk
chutikarn khamsukSCSomruethai Channasanon
Somruethai ChannasanonSTSiriporn Tanodekaew
Siriporn Tanodekaew
Piyaphong Panpisut +2
The aim of this study was to prepare RMGICs for pulp protection that contain polyacids functionalized with methacrylate groups (CMs) to enable light-activated polymerization without the need for toxic 2-hydroxyethyl methacrylate (HEMA) monomers. The effects of using CM liquids with 0 or 5 wt% HEMA on the physical/mechanical properties and cytotoxicity of the experimental RMGICs were assessed. Spherical pre-reacted glass fillers (SPG) were used as the powder phase. The experimental RMGICs were prepared by mixing SPG with CM liquid (0 wt% HEMA, F1) or CMH liquid (5 wt% HEMA, F2). Commercial materials (Vitrebond, VB; TheraCal LC, TC) were used for the comparisons. The degree of monomer conversion and fluoride release of both F1 and F2 were significantly lower than those of VB. F1 showed comparable biaxial flexural strength with VB but higher strength than TC. The dimensional stability (mass/volume changes) of the experimental materials was comparable with that of the commercial materials. F1 and F2 exhibited higher Sr/Ca ion release and relative cell viability than VB. The use of CMH liquid reduced the strength but enhanced the fluoride release of the experimental RMGICs. In conclusion, the experimental RMGICs showed comparable strength but lower cytotoxicity compared to the commercial RMGICs. These novel materials could be used as alternative materials for pulp protection.
Journal Article
WISITSIN POTIPRAPANPONGPNParichart Naruphontjirakul
Parichart NaruphontjirakulCKchutikarn khamsuk
chutikarn khamsukSCSomruethai Channasanon
Somruethai Channasanon
Arnit ToneluckPiyaphong Panpisut +3
This study prepared low-toxicity, elemental-releasing resin-modified glass ionomer cements (RMGICs). The effect of 2-hydroxyethyl methacrylate (HEMA, 0 or 5 wt%) and Sr/F-bioactive glass nanoparticles (Sr/F-BGNPs, 5 or 10 wt%) on chemical/mechanical properties and cytotoxicity were examined. Commercial RMGIC (Vitrebond, VB) and calcium silicate cement (Theracal LC, TC) were used as comparisons. Adding HEMA and increasing Sr/F-BGNPs concentration decreased monomer conversion and enhanced elemental release but without significant effect on cytotoxicity. Rising Sr/F-BGNPs reduced the strength of the materials. The degree of monomer conversion of VB (96%) was much higher than that of the experimental RMGICs (21–51%) and TC (28%). The highest biaxial flexural strength of experimental materials (31 MPa) was significantly lower than VB (46 MPa) (p < 0.01) but higher than TC (24 MPa). The RMGICs with 5 wt% HEMA showed higher cumulative fluoride release (137 ppm) than VB (88 ppm) (p < 0.01). Unlike VB, all experimental RMGICs showed Ca, P, and Sr release. Cell viability in the presence of extracts from experimental RMGICs (89–98%) and TC (93%) was significantly higher than for VB (4%). Experimental RMGICs showed desirable physical/mechanical properties with lower toxicity than the commercial material.
Journal Article
Whithipa ThepveeraWISITSIN POTIPRAPANPONGArnit ToneluckSCSomruethai Channasanon
Somruethai ChannasanonCKchutikarn khamsuk
chutikarn khamsukPiyaphong Panpisut +2
The aim of this study was to prepare experimental resin-modified glass ionomer cements (RMGICs) containing low levels of hydroxyethyl methacrylate (HEMA) for pulp protection. Liquid and powder phases of the experimental RMGICs were polyacid functionalized with methacrylate groups and spherical pre-reacted glass fillers (SPG). Two types of liquid phase containing 0 wt. % HEMA (CM liquid) or 5 wt. % HEMA (CMH liquid) were formulated. The experimental RMGICs were prepared by mixing SPG fillers with CM liquid (F1) or CMH liquid (F2). Rheological properties were examined using a strain-controlled rheometer (n = 5). The Vickers microhardness (n = 5) and dentin shear bond strength (SBS) (n = 10) of the materials were tested. Commercial pulp protection materials (Vitrebond and TheraCal LC) were used as comparisons. The viscosity and surface microhardness of F1 (22 m Pa·s, 18 VHN) and F2 (18 m Pa·s, 16 VHN) were significantly higher than those of Vitrebond (6 mPa·s, 6 VHN) and TheraCal (0.1 mPa·s, 7 VHN). The SBS of F1 (10.7 MPa) and F2 (11.9 MPa) was comparable to that of Vitrebond (15.4 MPa) but higher than that of TheraCal LC (5.6 MPa). The addition of 5 wt. % HEMA showed no significant effect on viscosity, surface microhardness, or SBS of the experimental RMGICs. The experimental materials showed higher viscosity and microhardness but similar SBS when compared with the commercial RMGIC.
Journal Article
TSTeerawat Sukpaita
Teerawat SukpaitaSCSuwabun Chirachanchai
Suwabun ChirachanchaiTCTheerapat Chanamuangkon
Theerapat ChanamuangkonKNKatanchalee Nampuksa
Katanchalee NampuksaNaruporn MonmaturapojRARuchanee Salingcarnboriboon Ampornaramveth
Ruchanee Salingcarnboriboon Ampornaramveth +2
Bone tissue engineering is a complicated field requiring concerted participation of cells, scaffolds, and osteoactive molecules to replace damaged bone. This study synthesized a chitosan-based (CS) scaffold incorporated with trichostatin A (TSA), an epigenetic modifier molecule, to achieve promising bone regeneration potential. The scaffolds with various biphasic calcium phosphate (BCP) proportions: 0%, 10%, 20%, and 40% were fabricated. The addition of BCP improved the scaffolds’ mechanical properties and delayed the degradation rate, whereas 20% BCP scaffold matched the appropriate scaffold requirements. The proper concentration of TSA was also validated. Our developed scaffold released TSA and sustained them for up to three days. The scaffold with 800 nM of TSA showed excellent biocompatibility and induced robust osteoblast-related gene expression in the primary human periodontal ligament cells (hPDLCs). To evaluate in vivo bone regeneration potential, the scaffolds were implanted in the mice calvarial defect model. The excellent bone regeneration ability was further demonstrated in the micro-CT and histology sections compared to both negative control and commercial bone graft product. New bone formed in the CS/BCP/TSA group revealed a trabeculae-liked characteristic of the mature bone as early as six weeks. The CS/BCP/TSA scaffold is an up-and-coming candidate for the bone tissue engineering scaffold.
14 June 2023 in Clinical Oral Implants Research
Journal Article
SASirida Arunjaroensuk
Sirida ArunjaroensukPTPasutha Thunyakitpisal
Pasutha ThunyakitpisalKNKatanchalee Nampuksa
Katanchalee Nampuksa
Naruporn MonmaturapojNMNikos Mattheos
Nikos MattheosAPAtiphan Pimkhaokham
Atiphan Pimkhaokham5 February 2024 in Clinical Implant Dentistry and Related Research
Journal Article
SASirida Arunjaroensuk
Sirida ArunjaroensukKNKatanchalee Nampuksa
Katanchalee Nampuksa
Naruporn MonmaturapojPTPasutha Thunyakitpisal
Pasutha ThunyakitpisalTPThantrira Porntaveetus
Thantrira PorntaveetusAPAtiphan Pimkhaokham
Atiphan Pimkhaokham +1
About Me
Ph. D. in Ceramic Science and Engineering, University of Sheffield, UK, 2005
M. Sc. in Ceramic Science and Engineering, University of Sheffield, UK, 2001
M. Eng. in Industrial Engineering, Chulalongkorn University, Bangkok, Thailand, 2000
B. Eng. in Industrial Engineering, Prince of Songkla University, Songkla, Thailand, 1996
2018-Present:
Principal researcher in Implantable Medical Devices Technology Team, Assistive Technology and Medical Devices Research Center (A-MED), National Metal and Materials Technology Center (MTEC), National Science and Technology Development Agency (NSTDA), Ministry of Science and Technology. Mainly working on synthesize, fabrication and characterization of bioceramics and bioglass ceramics projects. Responsibility as Quality Management Representative (QMR) in ISO 13485 system for Implantable Medical Devices Technology Team.
2005-2017:
Researcher in Biomaterials Laboratory, Biomedical Engineering Research Unit, National Metal and Materials Technology Center (MTEC), National Science and Technology Development Agency (NSTDA), Ministry of Science and Technology. Mainly working on synthesize, fabrication and characterization of bioceramics and bioglass ceramics projects.
Quality management representative (QMR): take responsible as quality management representative (QMR) and internal auditor for ISO 13485 in the research and development of hydroxyapatite bone graft at Biomaterial Laboratory, Biomedical Engineering Research Unit, MTEC.